Bar Harbor, ME
The primary research goals of the Lutz lab involve developing preclinical mouse models of neurodegeneration to test therapeutics and inform clinical trials.
Dr. Lutz is Director of the Mouse Repository and the Rare and Orphan Disease Center at The Jackson Laboratory. She has fiscal and managerial oversight of a growing collection of more than 8,500 unique strains, including over 1,700 live colonies for distribution to the scientific community. As part of the Mouse Repository program, Dr. Lutz is the Principal investigator on a number of NIH sponsored resource grants, including the Mutant Mouse Regional and Research Center at JAX, The SMSR grant to support recombinant inbred and Chromosome substitution panels, as well as the NICHD Cytogenetic Resource to support Down Syndrome related strains and research. Dr. Lutz also serves as the Director of In Vivo Pharmacology and Efficacy Testing Program in Bar Harbor, which interfaces with biotechnology and pharmaceutical companies to pursue novel therapeutics across a variety of therapeutic areas.
A neuroscientist by training, Dr. Lutz conducts research in neurodegenerative diseases, including Spinal Muscular Atrophy (SMA), Friedreich’s ataxia, Amyotrophic Lateral Sclerosis (ALS) and Frontotemperal Lobe Dementia (FTD. Her lab works closely with multiple disease foundations and researchers in the development, characterization and validation of mouse models that support their research and drug discovery goals. These organizations include The ALS Association, The Friedreich’s Ataxia Research Alliance, the Spinal Muscular Atrophy (SMA) Foundation, Cure SMA, and the Grace Science Foundation.
University of Maine, Orono, ME
The University of Pittsburgh, Pittsburgh, PA
Director, Repository, and Research Scientist, Genetic Resource Science, The Jackson Laboratory, Bar Harbor, ME
Associate Director and Research Scientist, Genetic Resource Science, The Jackson Laboratory, Bar Harbor, ME
Mouse Repository Operations Manager and Associate Research Scientist, The Jackson Laboratory, Bar Harbor, ME
Senior Scientific Curator, Mouse Genome Informatics, The Jackson Laboratory, Bar Harbor, ME
Postdoctoral Associate, Laboratory of Dr. David Hosford, Duke University, Durham North Carolina
Predoctoral Associate, Laboratory of Dr. Wayne Frankel, The Jackson Laboratory, Bar Harbor, ME
Senior Research Assistant, Laboratory of Dr. Wayne Frankel, The Jackson Laboratory, Bar Harbor, ME
Research Assistant, Laboratory of Dr. Benjamin Taylor, The Jackson Laboratory, Bar Harbor, ME
Research Technician, Laboratory of Dr. Mary Edmonds, The University of Pittsburgh, Pittsburgh, PA
A mouse model of spinal muscular atrophy developed at The Jackson Laboratory lay the foundation for the successful clinical trials of a new SMA drug, Spinraza.
Most cases of amyotrophic lateral sclerosis (ALS) are sporadic, meaning that there is no family history of the disease.
In work involving several new generations of mouse model development, Jackson Laboratory (JAX) researchers have tested a therapeutic intervention for spinal muscular atrophy (SMA) that restores some function lost due to a mutation in one gene (SMN1) and amplifies the levels of protective genes (SMN2). Moreover, unlike current interventions, the therapy appears to work after symptoms of SMA have already appeared, and may not need to be administered directly into the central nervous system.
Two 2011 studies demonstrate that restoring or increasing spinal motor neuron (SMN) protein alleviates or even reverses disease in spinal muscular atrophy (SMA) mouse models.
Australian researcher Sarah Stephenson wanted to fast-track her research of Parkinson's disease, so she shuffled the genetic deck using a new experimental platform at The Jackson Laboratory.
Scientists are rapidly engineering mice that model these genetic lesions which will be critical for understanding pathogenesis of these diseases.
A novel, allelic series of spinal muscular atrophy (SMA) mouse models have been created that differ in SMN expression levels and SMA-related disease severity.
Huntington's disease hasn't stopped Cathy Alley from pursuing her passion for live music or supporting the search for cures for her disease.
Advance your research in genetics by harnessing the power of the mouse! This new graduate-level advanced genetics course will provide a...
This workshop provides training in the use of genetically defined laboratory mice as tools for asking questions about gene function and the...
This new video from The Cox Lab video offers an inside look at the research goals of Amy Hicks, a postdoctoral associate who is studying...
About 80 percent of rare diseases are genetic in origin, about half affect children, many are fatal, and very few have...
Rare and Orphan Disease Research Tools and Online Resources
Efficacy studies are performed by JAX on mouse models for these diseases: C57BL10.mdx and D2.mdx for DMD, DyW for CMD1A, and A/J for...
We partner with foundations, pharmaceutical and biotech companies, and other scientists to research treatments for uncommon...
JAX distributes well-characterized, preclinical mouse models to accelerate drug discovery for rare and orphan diseases.
We engineer new models and enhance existing models through genetic standardization and characterization to ensure reproducibility of data...
Families have banded together from across the globe to make awareness and research for SMARD a reality.
Genetic diversity should be accounted for in pre-clinical tests, and researchers need to select the right model system to mimic human...
A team from The Jackson Laboratory attended a Rare Disease Day 2016 event in Maine to help educate state legislators and staff about the...
JAX Professor Robert Burgess and collaborators are developing personalized gene therapy for a Texas child suffering from a neuromuscular...
Cortney Lavorgna is a college student who is exploring the neuromuscular disease she lives with in a JAX research...
Over 30,000 peer-reviewed publications cite use of JAX® Mice strains. Hundreds of new papers referencing JAX® Mice strains are published...